DEALS: Actavis buys Amide Pharmaceuticals


Actavis buys Amide Pharmaceuticals


DEALS

WHO

WITH

WHAT

SCOOP

Bionomics

Iliad Chemicals

$9M buyout

The deal is intended to help beef up Bionomics' pipeline toward its goal of having two Phase II products and five preclinical programs by 2008.

Actavis

Amide Pharmaceuticals

$500M buyout

The buyout gives Actavis a much bigger beachhead in the American generics market, making it easier to sell generic drugs and introduce new pharmaceuticals.  

Cephalon

Salmedix

$160M buyout

Researchers at Salmedix have been testing Treanda as both a treatment for non-Hodgkin's lymphoma for patients who have not responded to Rituxan and a complement to Rituxan.

Invitrogen

Caltag Laboratories

$20M buyout

The deal adds Caltag's library of antibodies to Invitrogen's rapidly expanding stockpile.

BioXell

Merck

$150M drug development pact

Merck has agreed to pay up to that amount to develop the company's lead product, TREM-1, which targets a receptor on specific immune cells.

Lexicon Genetics

Organon Labs

Drug collaboration

The research work will concentrate on 300 genes that encode therapeutic antibodies and proteins.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.